Bell Potter: Telix’s $2.35B ITM deal boosts isotope supply-chain exposure
Bell Potter analyst John Hester says Telix’s US$2.35 billion acquisition of ITM provides “unparalleled exposure” to the supply chain for cancer treatments’ dominant therapeutic isotope, citing ITM’s role as a leading manufacturer.